Prevalence of Migraine in General Spanish Population; Factors Related and Use of Health Resources

Salazar, Alejandro; Berrocal, Laura; Failde, Inmaculada

doi:10.3390/ijerph182111145

Cited by 5 publications

(3 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Migraine causes severe impairment, influencing the quality of life, and the patients are unable to be productive in their daily activities [79,80]; consequently, migraine has a considerable economic impact on societies [81]. In an attempt to offer effective and personalized treatment, genetic studies are paving the way towards "precision medicine" targeted healthcare strategies, that take into account an individual's genetic make-up and other environmental factors, to offer the optimal therapeutic and preventive options for each case.…”

Section: Discussionmentioning

confidence: 99%

Deciphering the Role of the rs2651899, rs10166942, and rs11172113 Polymorphisms in Migraine: A Meta-Analysis

et al. 2022

View full text Add to dashboard Cite

The genetic basis of migraine is rather complex. The rs2651899 in the PR/SET domain 16 (PRDM16) gene, the rs10166942 near the transient receptor potential cation channel subfamily M member 8 (TRPM8) gene, and the rs11172113 in the LDL receptor-related protein 1 (LRP1) gene, have been associated with migraine in a genome-wide association study (GWAS). However, data from subsequent studies examining the role of these variants and their relationship with migraine remain inconclusive. The aim of the present study was to meta-analyze the published data assessing the role of these polymorphisms in migraine, migraine with aura (MA), and migraine without aura (MO). We performed a search in the PubMed, Scopus, Web of Science, and Public Health Genomics and Precision Health Knowledge Base (v7.7) databases. In total, eight, six, and six studies were included in the quantitative analysis, for the rs2651899, rs10166942, and rs11172113, respectively. Cochran’s Q and I2 tests were used to calculate the heterogeneity. The random effects (RE) model was applied when high heterogeneity was observed; otherwise, the fixed effects (FE) model was applied. The odds ratios (ORs) and the respective 95% confidence intervals (CIs) were calculated to estimate the effect of each variant on migraine. Funnel plots were created to graphically assess publication bias. A significant association was revealed for the CC genotype of the rs2651899, with the overall migraine group (RE model OR: 1.32; 95% CI: 1.02–1.73; p-value = 0.04) and the MA subgroup (FE model OR: 1.40; 95% CI: 1.12–1.74; p-value = 0.003). The rs10166942 CT genotype was associated with increased migraine risk (FE model OR: 1.36; 95% CI: 1.18–1.57; p-value < 0.0001) and increased MO risk (FE model OR: 1.41; 95% CI: 1.17–1.69; p-value = 0.0003). No association was detected for the rs11172113. The rs2651899 and the rs10166942 have an effect on migraine. Larger studies are needed to dissect the role of these variants in migraine.

show abstract

Section: Discussionmentioning

confidence: 99%

Deciphering the Role of the rs2651899, rs10166942, and rs11172113 Polymorphisms in Migraine: A Meta-Analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Migraine is a debilitating neurological condition with an overall prevalence of approximately 15% in Europe [ 1 ], and 1-year prevalences of 12.6% in Spain [ 2 ] and 16.6% in Germany [ 3 ]. Reported prevalence estimates vary between studies, possibly due to differences in study design and/or inclusion criteria [ 4 , 5 ]. Migraine is more prevalent in females (17.6%) than males (8%) in Europe [ 1 ], and is most common between the ages of 15 and 49 years, with the highest prevalence (~ 30%) in females aged 35–39 years [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Acute Treatment Patterns, Migraine Burden, and Healthcare Resource Use in People With Migraine: Results From the OVERCOME (EU) Observational Study

Evers,

Dell’Agnello,

Novick

et al. 2024

Pain Ther

View full text Add to dashboard Cite

Introduction The ObserVational survey of the Epidemiology, tReatment and Care Of MigrainE (OVERCOME) European Union (EU) is part of an overarching population-based study program that also includes the United States and Japan. Here, we report data on the migraine/severe headache burden and the use of acute medication and healthcare resources in Spain and Germany. Methods OVERCOME (EU) was an online, non-interventional, cross-sectional survey conducted in adults in Spain and Germany between October 2020 and February 2021. A total migraine cohort was established based on health survey participants who reported headache/migraine in the last 12 months AND identified as having migraine based on modified International Classification of Headache Disorders, third edition criteria OR self-reported physician diagnosis. Data were analyzed for the total migraine cohort and the subcohort with moderate to severe headache attacks, with average pain severity ≥ 5 points, pain duration ≥ 4 h, and at least moderate disability due to migraine [Migraine Disability Assessment (MIDAS) score ≥ 11] over the past 3 months. Results Pain of moderate or severe intensity was the most frequent symptom in the total migraine cohort ( n = 19,103/20,756; 92.0%). Proportions of participants reporting severe disability (MIDAS Grade IV), poorer quality of life (QoL; Migraine-Specific QoL Questionnaire), and higher interictal burden (Migraine Interictal Burden Scale-4), generally increased with number of headache days (HDs)/month. Most participants (92.5%) reported current acute migraine/severe headache medication use, although only 39.0% were using triptans. In the moderate to severe attacks subcohort ( n = 5547), 48.4% were using triptans, with nonsteroidal anti-inflammatory drugs the most common acute medication. The moderate to severe attacks subcohort also reported poorer QoL and greater pain and disability with increasing HDs/month, although severe interictal burden was reported for ~ 60% of participants regardless of HDs/month. Treatment satisfaction (six-item migraine Treatment Optimization Questionnaire) in those using triptans was generally poor in both total and subcohorts. Conclusion High migraine-related burden levels were reported, despite use of acute medication. Although triptans are recommended for moderate to severe migraine attacks in Spanish and German guidelines, less than half of participants were using triptans; treatment satisfaction in those using triptans was generally poor. New tailored treatment options may help address unmet needs in current acute treatment. Supplementary Information The online version contains supplementary material available at 10.1007/s40122-024-00589-3.

show abstract

“…Psychological distress (e.g., anxiety, depression, and specific comorbid functional disorders) increases the symptom burden and functional impairment in several chronic medical conditions (e.g., headaches) [ 19 , 20 , 21 , 22 ]. For example, approximately half of acute TMD patients and 10% of headache sufferers have comorbid anxiety disorders, indicating that anxiety may be an early feature in both patient populations [ 20 ].…”

Section: Introductionmentioning

confidence: 99%

Headache Because of Problems with Teeth, Mouth, Jaws, or Dentures in Chronic Temporomandibular Disorder Patients: A Case–Control Study

Ostrc

Frankovič²,

Pirtošek

et al. 2022

IJERPH

View full text Add to dashboard Cite

This study aimed to characterize self-reported headaches because of problems with the teeth, mouth, jaws, or dentures (HATMJD) in chronic patients with temporomandibular disorders (TMDs) in order to compare their results with those of TMD patients without such headaches and to investigate the associations of HATMJD with depression, anxiety, physical symptoms, oral behaviors, and sleep quality. We conducted a case–control study on consecutive chronic TMD patients referred to the University Medical Center of Ljubljana, Slovenia. A self-reported HATMJD was extracted from item #12 in the 49-item version of the Oral Health Impact Profile questionnaire. Axis II instruments of the Diagnostic Criteria for TMD (i.e., for screening of depression, anxiety, specific comorbid functional disorders, and oral behaviors) and the Pittsburgh Sleep Quality Index were used in this study. In total, 177 TMD patients (77.4% women; mean age: 36.3 years) participated in this study; 109 (61.6%) patients were classified as TMD patients with HATMJD. TMD patients with at least mild depressive and anxiety symptoms, with at least low somatic symptom severity, and a high number of parafunctional behaviors had more HATMJD. Parafunctional behavior and sleep quality were the most prominent predictive factors of the occurrence of HATMJD. TMD patients with HATMJD have more psychosocial dysfunction, a higher frequency of oral behaviors, and poorer sleep quality than TMD patients without such headaches.

show abstract

Prevalence of Migraine in General Spanish Population; Factors Related and Use of Health Resources

Cited by 5 publications

References 40 publications

Deciphering the Role of the rs2651899, rs10166942, and rs11172113 Polymorphisms in Migraine: A Meta-Analysis

Deciphering the Role of the rs2651899, rs10166942, and rs11172113 Polymorphisms in Migraine: A Meta-Analysis

Acute Treatment Patterns, Migraine Burden, and Healthcare Resource Use in People With Migraine: Results From the OVERCOME (EU) Observational Study

Headache Because of Problems with Teeth, Mouth, Jaws, or Dentures in Chronic Temporomandibular Disorder Patients: A Case–Control Study

Contact Info

Product

Resources

About